Ignite Creation Date:
2024-10-25 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06539793
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence after lumbar pain and osteoarthritis Its prevalence is around 2-4 and is more frequent in women than in men the prevalence is highest in age the range of 40-60 years
Detailed Description:
Group A Control Group Patients will receive exercises and sham Non-Invasive Neuromodulation 3 sessions per week one hour for each session for 4 weeks
Group B Study Group Patients will receive exercises as in group A in addition to Non-Invasive Neuromodulation 3 sessions per week one hour for each session for 4 weeks
Group B Study Group Patients will receive exercises as in group A in addition to Non-Invasive Neuromodulation 3 sessions per week one hour for each session for 4 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None